M710

Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar
Drug Delivery Business News
Thu, 01/4/18 - 11:01 am
Mylan Labs
Momenta Pharmaceuticals
Regeneron
Eylea
biosimilars
diabetic macular edema
wet age-related macular degeneration
M710